Interaction Checker

Interaksi Metilnaltrekson

Metilnaltrekson (Relistor), golongan antagonis opioid, memiliki 52 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 43 mayor, 2 moderat, 0 minor, dan 7 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (43)

  • Alvimopanantagonis opioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Beladona dan opiumopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Biktegravir, emtrisitabin, dan tenofovir alafenamidantiretroviralMayor

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (label Biktegravir, emtrisitabin, dan tenofovir alafenamid, Interaksi obat)

  • BuprenorfinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Buprenorfin dan naloksonopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Butalbital, aspirin, kafein, dan kodeinbarbituratMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Butalbital, parasetamol, kafein, dan kodeinbarbituratMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • ButorfanolopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • DarunavirantiretroviralMayor

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (label Darunavir, Kontraindikasi)

  • Darunavir dan kobisistatantiretroviralMayor

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (label Darunavir dan kobisistat, Kontraindikasi)

  • EluksadolinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • FentanilopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • HidrokodonopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Hidrokodon dan homatropinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Hidrokodon dan ibuprofenopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Hidrokodon dan klorfeniraminopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Hidrokodon dan parasetamolopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • HidromorfonopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • KodeinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • LenakapavirantiretroviralMayor

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (label Lenakapavir, Interaksi obat)

  • LevorfanolopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • MetadonopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • MorfinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • NalbufinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Naldemedinantagonis opioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Nalmefenantagonis opioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Naloksegolantagonis opioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Naloksonantagonis opioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Naltreksonantagonis opioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Naltrekson dan bupropionantagonis opioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (label Nirmatrelvir dan ritonavir, Kontraindikasi)

  • OksikodonopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Oksikodon dan parasetamolopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • OksimorfonopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • OliseridinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Parasetamol dan kodeinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Pentazosin dan naloksonopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • PetidinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Prometazin dan kodeinopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • RemifentanilopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • TapentadolopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • TramadolopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

  • Tramadol dan parasetamolopioidMayor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (label Metilnaltrekson, Interaksi obat)

Interaksi moderat (2)

  • EtravirinantiretroviralModerat

    Narcotic analgesics/treatment of opioid dependence: buprenorphine buprenorphine/naloxone methadone ↔ etravirine ↓ buprenorphine ↔ norbuprenorphine ↔ methadone Etravirine and buprenorphine (or buprenorphine/naloxone) can be co-administered without dose adjustments, however, clinical monitoring for withdrawal symptoms is recommended as buprenorphine (or buprenorphine/naloxone)… (label Etravirin, Interaksi obat)

  • Lofeksidinagonis alfa-adrenergikModerat

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (label Lofeksidin, Interaksi obat)

Tidak ada interaksi bermakna yang dilaporkan (7)

  • AkamprosatTanpa interaksi

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (label Akamprosat, Interaksi obat)

  • Bromfeniramin, pseudoefedrin, dan dekstrometorfanantihistaminTanpa interaksi

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (label Metilnaltrekson, Interaksi obat)

  • Dekstrometorfanobat serotonergikTanpa interaksi

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (label Metilnaltrekson, Interaksi obat)

  • Dekstrometorfan dan kuinidinobat serotonergikTanpa interaksi

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (label Metilnaltrekson, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralTanpa interaksi

    Narcotic Analgesics: buprenorphine/ naloxone ↑ buprenorphine ↑ norbuprenorphine ↓ naloxone No dosage adjustment of buprenorphine/naloxone is required upon coadministration with GENVOYA. (label Elvitegravir, kobisistat, emtrisitabin, dan tenofovir, Interaksi obat)

  • Emtrisitabin dan tenofovirantiretroviralTanpa interaksi

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (label Emtrisitabin dan tenofovir, Interaksi obat)

  • Prometazin dan dekstrometorfanantihistaminTanpa interaksi

    Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (label Metilnaltrekson, Interaksi obat)

Periksa Metilnaltrekson terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.